WEKO3
アイテム
Interleukin-2(IL-2)とCyclophosphamide(Cy)併用脾臓内直接投与によるマウス肝転移腫瘍の治療とその機構解析
https://kindai.repo.nii.ac.jp/records/2002267
https://kindai.repo.nii.ac.jp/records/200226761f455c3-9efc-4ab5-a0ad-739503b98a39
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
AN00063584-19930325-0137.pdf (2.5 MB)
|
|
| Item type | ☆紀要論文 / Departmental Bulletin Paper(1) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2025-01-17 | |||||||||||||
| タイトル | ||||||||||||||
| タイトル | Interleukin-2(IL-2)とCyclophosphamide(Cy)併用脾臓内直接投与によるマウス肝転移腫瘍の治療とその機構解析 | |||||||||||||
| 言語 | ja | |||||||||||||
| タイトル | ||||||||||||||
| タイトル | Immunotherapy with Interleukin-2 plus Cyclophosphamide in murine metastatic liver tumor | |||||||||||||
| 言語 | en | |||||||||||||
| 著者 |
中嶋, 一三
× 中嶋, 一三
× 奥野, 清隆
|
|||||||||||||
| 言語 | ||||||||||||||
| 言語 | jpn | |||||||||||||
| キーワード | ||||||||||||||
| 主題 | interleukin-2, cytokines, cyclophosphamide, lymphokine-activated killer cells, intrasplenic injection | |||||||||||||
| 資源タイプ | ||||||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||||||
| 資源タイプ | departmental bulletin paper | |||||||||||||
| 出版タイプ | ||||||||||||||
| 出版タイプ | AM | |||||||||||||
| 出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||||||||||
| 出版者 名前 | ||||||||||||||
| 出版者 | 近畿大学医学会 | |||||||||||||
| 言語 | ja | |||||||||||||
| bibliographic_information |
ja : 近畿大学医学雑誌 en : Medical Journal of Kinki University 巻 18, 号 1, p. 137-148, 発行日 1993-03-25 |
|||||||||||||
| ISSN | ||||||||||||||
| 収録物識別子タイプ | PISSN | |||||||||||||
| 収録物識別子 | 03858367 | |||||||||||||
| 内容記述 | ||||||||||||||
| 内容記述タイプ | Abstract | |||||||||||||
| 内容記述 | The clinical results of LAK therapy using interleukin-2 (IL-2) have not been satisfactory in the numerous investigations thus far conducted. Combinations of several lymphokines with IL-2 also have not produced adequate efficacy. However, combined chemo-immunotherapy with IL-2 plus Cyclophosphamide (Cy) has not been examined. We evaluated the effects of the combination of IL-2 plus Cy, injected directly into tumorbearing mouse spleens, on inhibition of tumor metastases. Colon 26 syngeneic tumor cells (5×10^5) were injected into BALB/c mouse portal veins. Ten days after tumor cell inoculation, Hank's solution, IL-2 (500 IU), Cy (40 μg), or IL-2 (500 IU) plus Cy (40 μg) was injected directly into the spleen of each mouse for 7 consecutive days. Seven days after cessation of treatment, lymphokine-activated killer (LAK) cell activity was enhanced in splenocytes from mice treated with IL-2 plus Cy in comparison with those from control mice. In vivo antitumor activity, as analyzed by a Kaplan-Meier life table, also resulted in significantly prolonged survival in the group treated with IL-2 plus Cy compared with that in the control group. Histological findings revealed prominent lymphoid cell proliferation in the spleen, and no metastatic foci were found in the liver. Furthermore, electron microscopic analysis showed that lymphoid cells, particularly large granular lymphocytes and Pit cells, constituents of the sinusoidal wall of the liver, were increased in the liver after intrasplenic injection of IL-2 plus Cy. These findings suggested that direct injection of IL-2 plus Cy into the tumor-bearing spleen contributed to activation of lymphoid cells present in the liver, and resulted in prolonged mouse survival time. Therefore, intrasplenic injection of a combination of IL-2 plus Cy may be a suitable strategy for the clinical treatment of metastatic liver tumor. | |||||||||||||
| 言語 | en | |||||||||||||
| 内容記述 | ||||||||||||||
| 内容記述タイプ | Other | |||||||||||||
| 内容記述 | 本文データはCiNiiから複製したものである。 | |||||||||||||
| 言語 | ja | |||||||||||||
